ENBIS-22 Trondheim Conference

Session

CONTRIBUTED Clinical Statistics/Anomalies

27 Jun 2022, 14:40

EL2

Conveners

CONTRIBUTED Clinical Statistics/Anomalies

• Jean-Michel Poggi (University of Paris-Saclay)

5. Detecting spatio-temporal anomalies in Italian mortality during the first year of the COVID-19 pandemic.

Piercesare Secchi (Politecnico di Milano - Department of Mathematics)

27/06/2022, 14:40

Clinical trials and tests

From the perspective of anomaly detection when data are functional and spatially dependent, we explore death counts from all causes observed along 2020 in the provinces and municipalities of Italy. Our aim is to isolate the spatio-temporal perturbation brought by COVID-19 to the Country’s expected process of mortality during the first two waves of the pandemic.

Within the framework of...

48. Is the difference in means always a good measure for an effect?

Mr Øystein Evandt (Evandt Industrial Statistics)

27/06/2022, 15:00

Clinical trials and tests

When comparing a medical treatment with placebo it is usual to apply a two-sample t-test. n1 patients are given treatment and n2 patients are given placebo. The standard assumptions for using a two-sample t-test are assumed. It is also assumed that large response values in the treatment group are desirable. Usually H0: “The distribution means are equal” is tested against H1: “The distribution...

113. GENEOnet: a GENEO based approach to Pocket Detection.

Dr Giovanni Bocchi (Department of Environmental Science and Policy, University of Milan)

27/06/2022, 15:20

Clinical trials and tests

Pocket detection is a key step inside the process of drug design and development. Its purpose is to prioritize specific areas of the protein surface with high chance of being binding sites. The primary byproduct of this is to avoid blind docking. During a blind docking, the software tries to fit the ligand into the target protein without prior knowledge, thus it scans the whole protein surface...